High-Throughput Analysis Enabled by Ultra-Fast Gradient with Nexera X4 × LCMS-8060 Series

Significance of the Topic

Liquid chromatography–tandem mass spectrometry (LC‑MS/MS) is increasingly adopted beyond specialized research laboratories into clinical and high‑throughput environments such as drug discovery and pharmacokinetics. Reducing per‑sample analysis time while preserving quantitative accuracy and chromatographic performance directly increases laboratory throughput and reduces turnaround time for large sample sets. Ultra‑fast gradients combined with minimized system dispersion and robust mass spectrometer switching extend LC‑MS/MS utility into workflows that demand both speed and reliability.

Objectives and Study Overview

This technical report evaluates the performance of Shimadzu’s Nexera X4 UHPLC coupled with the LCMS‑8060RX triple quadrupole mass spectrometer for ultra‑fast gradient LC‑MS/MS. The goals were to demonstrate: improved gradient responsiveness and reduced gradient delay via low system volume and advanced pump design; minimized peak broadening between column and MS; reliable ultra‑fast positive/negative polarity switching; and retention time and quantitative reproducibility during sub‑minute analyses of CYP‑related probe compounds.

Methodology

Key experimental approach and conditions used to assess ultra‑fast LC‑MS/MS performance included:

• Chromatographic configuration: Shim‑pack Scepter C18, 20 mm × 2.1 mm i.d., 1.9 µm, column temperature 40 °C.
• Injection and flow: 1 µL injection (15 µL sample loop), 0.6 mL/min flow.
• Mobile phases: A = 0.05% formic acid in water; B = acetonitrile.
• Gradient program (total cycle 0.60 min): B 25% at 0.00 min → 60% at 0.10 min → 90% at 0.30–0.45 min → 25% at 0.46–0.60 min; effective measurement window used was 0.6 min (36 s) for separation.
• Mass spectrometry: LCMS‑8060RX triple quadrupole, ESI in positive and negative modes, MRM acquisition; UFswitching technology enabled 5 ms polarity switching; interface voltage ±1.0 kV; interface temperature 400 °C; DL 200 °C; block heater 400 °C; nebulizing 3 L/min; heating gas 15 L/min; drying gas 5 L/min.

Used Instrumentation

Instruments and consumables explicitly evaluated or highlighted:

• Nexera X4 UHPLC platform.
• LC‑40B X4 binary solvent delivery unit: four independently actuated plungers and a pressure feedback mechanism to reduce pulsation and enable ultra‑fast, stable gradients under high pressure.
• LCMS‑8060RX triple quadrupole mass spectrometer with UFswitching high‑voltage module for rapid positive/negative polarity switching (5 ms).
• Shim‑pack Scepter™ C18 analytical column (20 × 2.1 mm, 1.9 µm).
• Nexflow tubing for MS: dedicated low‑dispersion transfer tubing optimized to reduce post‑column peak broadening and preserve UHPLC separation performance at the MS inlet.

Main Results and Discussion

Performance highlights obtained in the evaluation:

• Ultra‑fast separation: Seven CYP‑related compounds (1′‑Hydroxy Bufuralol, Oxidized Nifedipine, Acetaminophen, 4′‑hydroxydiclofenac, 1‑hydroxymidazolam, Hydroxy Tolbutamide, 7‑Hydroxycoumarin) were separated with a total method cycle time of 0.6 minutes; effective chromatographic elution spanned ~36 seconds.
• Retention time reproducibility: RT %RSD ≈ 0.2%, demonstrating very stable retention even under aggressive gradient slopes and short column residence times.
• Quantitative reproducibility: Peak area %RSD values averaged around 5% (excellent for ultra‑fast methods), indicating robust quantitation capability.
• Polarity switching: UFswitching allowed 5 ms positive/negative transitions with no apparent loss of ion intensity and preservation of peak shape when multiple analytes eluted closely; this enables mixed‑polarity panels without the need for separate acquisitions.
• Pump performance and baseline stability: The LC‑40B X4’s independently actuated plungers and pressure feedback significantly reduced pulsation‑derived baseline noise and improved gradient responsiveness compared to typical UHPLC pumps, as evidenced by faster recovery to programmed compositions.
• Reduced system dispersion: Low internal volume design of Nexera X4 and Nexflow MS tubing minimized gradient delay and post‑column band broadening, critical for preserving peak sharpness in sub‑minute separations.

Benefits and Practical Applications

The combined system offers several practical advantages for high‑throughput analytical environments:

• Markedly increased sample throughput due to sub‑minute cycle times, improving productivity in drug discovery, pharmacokinetics, and clinical screening workflows.
• Maintained quantitative accuracy and precision despite rapid gradients and closely eluting analytes, enabling reliable concentration measurement in biological matrices.
• Flexible method design permitting mixed‑polarity analyte panels via ultra‑fast polarity switching, reducing the need for separate positive and negative runs.
• Lower chromatographic dispersion and enhanced baseline stability, simplifying method transfer and robustness across many samples.

Future Trends and Applications

Potential developments and uses based on the demonstrated capabilities include:

• Expanded adoption in large‑scale ADME/PK studies and clinical screening where instrument throughput is a limiting factor.
• Integration with automated sample preparation and robotic systems to form end‑to‑end high‑throughput platforms.
• Further miniaturization and optimization of transfer paths and interfaces to push cycle times even lower while retaining quantitative performance.
• Application to targeted panels in therapeutic drug monitoring, toxicology screening, and high‑throughput bioanalysis where mixed‑polarity, rapid assays are advantageous.

Conclusion

The Nexera X4 UHPLC paired with the LCMS‑8060RX demonstrates that ultra‑fast gradient LC‑MS/MS with preserved chromatographic resolution and quantitative reliability is achievable through low internal volume design, advanced pump mechanics, optimized transfer tubing, and rapid polarity switching. The approach enables large increases in sample throughput while maintaining reproducible retention times and acceptable quantitative precision, making it suitable for demanding drug discovery, pharmacokinetic, and high‑throughput clinical workflows.

References

This summary is based on the Shimadzu technical report: High‑Throughput Analysis Enabled by Ultra‑Fast Gradient with Nexera X4 × LCMS‑8060 Series, Kosuke Nakajima, Miho Kawashima, Keiko Matsumoto, Shimadzu Corporation, First Edition March 2026.